<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802735</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-CP-033</org_study_id>
    <nct_id>NCT02802735</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Two Part Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This two-part study was designed to evaluate the pharmacokinetics (PK) of single and multiple&#xD;
      doses of apremilast in healthy adult Korean males.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of two parts. Part 1 will evaluate the PK of ascending single doses of&#xD;
      apremilast. Part 2 will evaluate the PK of apremilast when administered as multiple doses&#xD;
      over 14 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 22, 2016</start_date>
  <completion_date type="Actual">August 5, 2016</completion_date>
  <primary_completion_date type="Actual">August 5, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Part 1 of the study was a 3-treatment period, 3-sequence crossover study. Part 2 was a parallel-group, placebo-controlled, single-period study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Part 1 was a randomized open-label crossover study. Part 2 was a randomized, double-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Maximum Observed Plasma Concentration (Cmax) of Apremilast</measure>
    <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
    <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</measure>
    <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast</measure>
    <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) for Apremilast</measure>
    <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Terminal Elimination Half-life (T1/2) for Apremilast</measure>
    <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)</measure>
    <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)</measure>
    <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Area Under the Plasma Concentration-time Curve During a Dosage Interval (AUCτ) for Apremilast</measure>
    <time_frame>Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose</time_frame>
    <description>Area under the plasma concentration-time curve during a dosage interval (tau) at steady state, where tau is 12 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Maximum Observed Plasma Concentration (Cmax) of Apremilast</measure>
    <time_frame>Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</measure>
    <time_frame>Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Terminal Elimination Half-life (T1/2) for Apremilast</measure>
    <time_frame>Day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours after the morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)</measure>
    <time_frame>Day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours after the morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)</measure>
    <time_frame>Day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours after the morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Ratio of Accumulation</measure>
    <time_frame>Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose, and on day 14 only at 24, 36, 48, 60, and 72 hours after the morning dose</time_frame>
    <description>Ratio of accumulation calculated as Day 14 AUC0-τ / Day 1 AUC0-τ</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (AEs)</measure>
    <time_frame>Part 1, up to 40 days; Part 2, up to 24 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Part 1: Apremilast 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 20 mg apremilast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Apremilast 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 30 mg apremilast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Apremilast 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 40 mg apremilast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Apremilast 30 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg apremilast orally twice a day (BID) for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo orally twice a day for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>Tablet for oral administration</description>
    <arm_group_label>Part 1: Apremilast 20 mg</arm_group_label>
    <arm_group_label>Part 1: Apremilast 30 mg</arm_group_label>
    <arm_group_label>Part 1: Apremilast 40 mg</arm_group_label>
    <arm_group_label>Part 2: Apremilast 30 mg BID</arm_group_label>
    <other_name>CC-10004</other_name>
    <other_name>OTEZLA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet for oral administration</description>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Subjects must satisfy the following criteria to be enrolled in the study:&#xD;
&#xD;
          1. Healthy adult male Korean subjects between 18 and 45 years of age (inclusive) at the&#xD;
             time of signing the informed consent form (ICF).&#xD;
&#xD;
          2. Subject must understand and voluntarily sign an ICF prior to any study-related&#xD;
             assessments/procedures being conducted.&#xD;
&#xD;
          3. Subject is willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
          4. Must be able to communicate with the Investigator and understand and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
          5. Must be in good health as determined by the Investigator according to past medical&#xD;
             history, physical examination (PE), vital signs, 12-lead electrocardiogram (ECG), and&#xD;
             laboratory tests.&#xD;
&#xD;
          6. Must have a body mass index (BMI) between 18 and 30 kg/m^2 (inclusive).&#xD;
&#xD;
          7. Clinical laboratory tests must be within normal limits or considered by the&#xD;
             Investigator to be not clinically significant.&#xD;
&#xD;
          8. Vital signs (systolic and diastolic blood pressure, pulse rate, and oral [or tympanic]&#xD;
             body temperature) will be assessed in the supine position after the subject has rested&#xD;
             for at least five minutes. Subject must be afebrile (febrile [oral or tympanic] is&#xD;
             defined as ≥ 38°C or 100.3°F) with vital signs within the following ranges:&#xD;
&#xD;
               -  Systolic blood pressure: 90 to 140 mm Hg;&#xD;
&#xD;
               -  Diastolic blood pressure: 50 to 90 mm Hg;&#xD;
&#xD;
               -  Pulse rate: 40 to 110 bpm.&#xD;
&#xD;
          9. Must have a normal or clinically acceptable 12-lead ECG. Subjects must have a QTc&#xD;
             value ≤ 450 msec.&#xD;
&#xD;
         10. Must have a normal or clinically acceptable physical examination.&#xD;
&#xD;
         11. Contraception Requirements:&#xD;
&#xD;
             - Male subjects (including those who have had a vasectomy) who engage in activity in&#xD;
             which conception is possible must use barrier contraception (latex or non-latex&#xD;
             condoms NOT made out of natural [animal] membrane [for example, polyurethane]) while&#xD;
             on Investigational Product (IP) and for at least 28 days after the last dose of&#xD;
             investigational product (IP).&#xD;
&#xD;
         12. Must agree to refrain from donating sperm, blood or plasma (other than for this study)&#xD;
             while participating in this study, and for at least 28 days after the last dose of IP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of any of the following will exclude any healthy subject from enrollment&#xD;
             into the study:&#xD;
&#xD;
               1. History of any clinically significant and relevant neurological, psychiatric,&#xD;
                  gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary,&#xD;
                  metabolic, endocrine, hematological, allergic disease, drug allergies, or other&#xD;
                  major disorders.&#xD;
&#xD;
               2. Any condition which places the subject at unacceptable risk if he were to&#xD;
                  participate in the study, or confounds the ability to interpret data from the&#xD;
                  study.&#xD;
&#xD;
               3. Use of any prescribed systemic or topical medication within 30 days of the first&#xD;
                  dose administration.&#xD;
&#xD;
               4. Use of any non-prescribed systemic or topical medication (including&#xD;
                  vitamin/mineral supplements, and herbal medicines) within 14 days of the first&#xD;
                  dose administration.&#xD;
&#xD;
               5. Any surgical or medical condition possibly affecting drug absorption,&#xD;
                  distribution, metabolism and excretion, eg, bariatric procedure, colon resection,&#xD;
                  irritable bowel syndrome, Crohn's disease, etc. Subjects with cholecystectomy and&#xD;
                  appendectomy may be included.&#xD;
&#xD;
               6. Exposure to an investigational drug (new chemical entity) within 30 days prior to&#xD;
                  the first dose administration or 5 half-lives of that investigational drug, if&#xD;
                  known (whichever is longer).&#xD;
&#xD;
               7. Donated blood or plasma within eight weeks before the first dose administration&#xD;
                  to a blood bank or blood donation center.&#xD;
&#xD;
               8. History of drug abuse (as defined by the current version of the Diagnostic and&#xD;
                  Statistical Manual [DSM]) within 2 years before dosing, or a positive drug screen&#xD;
                  reflecting consumption of illicit drugs.&#xD;
&#xD;
               9. History of alcohol abuse (as defined by the current version of the DSM) within 2&#xD;
                  years before dosing, or a positive alcohol screen.&#xD;
&#xD;
              10. Known to have hepatitis, or known to be a carrier of the hepatitis B surface&#xD;
                  antigen (HBsAg), or hepatitis C virus (HCV) antibodies, or have a positive result&#xD;
                  to the test for HBsAg, HCV antibodies or human immunodeficiency virus (HIV)&#xD;
                  antibodies at Screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT02802735?term=CC-10004-CP-033&amp;rank=1</url>
    <description>Expanded Access for CC-10004</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <results_first_submitted>June 14, 2021</results_first_submitted>
  <results_first_submitted_qc>June 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2021</results_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Apremilast</keyword>
  <keyword>Healthy Adult Male</keyword>
  <keyword>Korean Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a two-part study in healthy Korean men. The study was conducted at 1 clinic in Korea.</recruitment_details>
      <pre_assignment_details>In Part 1 participants were randomized to 1 of 3 treatment sequences consisting of 3 treatment periods.&#xD;
In Part 2 participants were randomized in a 3:1 ratio to receive apremilast or matching placebo twice a day (BID) for 14 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Apremilast 20 mg / 30 mg / 40 mg</title>
          <description>Participants received a single oral dose of 20 mg apremilast on day 1 of period 1, a single oral dose of 30 mg apremilast on day 1 of period 2, and a single oral dose of 40 mg apremilast on day 1 of period 3. There was a 7-10 day washout period between each dose.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: Apremilast 30 mg / 20 mg / 40 mg</title>
          <description>Participants received a single oral dose of 30 mg apremilast on day 1 of period 1, a single oral dose of 20 mg apremilast on day 1 of period 2, and a single oral dose of 40 mg apremilast on day 1 of period 3. There was a 7-10 day washout period between each dose.</description>
        </group>
        <group group_id="P3">
          <title>Part 1: Apremilast 40 mg / 20 mg / 30 mg</title>
          <description>Participants received a single oral dose of 40 mg apremilast on day 1 of period 1, a single oral dose of 20 mg apremilast on day 1 of period 2, and a single oral dose of 30 mg apremilast on day 1 of period 3. There was a 7-10 day washout period between each dose.</description>
        </group>
        <group group_id="P4">
          <title>Part 2: Apremilast 30 mg BID</title>
          <description>Participants received 30 mg apremilast orally twice a day for 14 days.</description>
        </group>
        <group group_id="P5">
          <title>Part 2: Placebo BID</title>
          <description>Participants received matching placebo orally twice a day for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Apremilast</title>
          <description>Participants received a single oral dose of 20 mg apremilast, 30 mg apremilast, and 40 mg apremilast across 3 treatment periods separated by a washout period of 7-10 days.</description>
        </group>
        <group group_id="B2">
          <title>Part 2: Apremilast 30 mg BID</title>
          <description>Participants received 30 mg apremilast orally twice a day for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Part 2: Placebo BID</title>
          <description>Participants received matching placebo orally twice a day for 14 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" lower_limit="19.0" upper_limit="43.0"/>
                    <measurement group_id="B2" value="30.8" lower_limit="24.0" upper_limit="41.0"/>
                    <measurement group_id="B3" value="25.5" lower_limit="20.0" upper_limit="31.0"/>
                    <measurement group_id="B4" value="29.6" lower_limit="19.0" upper_limit="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Maximum Observed Plasma Concentration (Cmax) of Apremilast</title>
        <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.</description>
        <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Apremilast 20 mg</title>
            <description>Participants received a single oral dose of 20 mg apremilast.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Apremilast 30 mg</title>
            <description>Participants received a single oral dose of 30 mg apremilast.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Apremilast 40 mg</title>
            <description>Participants received a single oral dose of 40 mg apremilast.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximum Observed Plasma Concentration (Cmax) of Apremilast</title>
          <description>Concentrations of apremilast in plasma were measured using a validated liquid chromatography tandem mass spectrometry assay.</description>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205" spread="32.1"/>
                    <measurement group_id="O2" value="273" spread="32.1"/>
                    <measurement group_id="O3" value="373" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</title>
        <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Apremilast 20 mg</title>
            <description>Participants received a single oral dose of 20 mg apremilast.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Apremilast 30 mg</title>
            <description>Participants received a single oral dose of 30 mg apremilast.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Apremilast 40 mg</title>
            <description>Participants received a single oral dose of 40 mg apremilast.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</title>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.5" upper_limit="5.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.5" upper_limit="5.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="0.5" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast</title>
        <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Apremilast 20 mg</title>
            <description>Participants received a single oral dose of 20 mg apremilast.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Apremilast 30 mg</title>
            <description>Participants received a single oral dose of 30 mg apremilast.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Apremilast 40 mg</title>
            <description>Participants received a single oral dose of 40 mg apremilast.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) for Apremilast</title>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1770" spread="25.8"/>
                    <measurement group_id="O2" value="2330" spread="22.6"/>
                    <measurement group_id="O3" value="3470" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) for Apremilast</title>
        <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Apremilast 20 mg</title>
            <description>Participants received a single oral dose of 20 mg apremilast.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Apremilast 30 mg</title>
            <description>Participants received a single oral dose of 30 mg apremilast.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Apremilast 40 mg</title>
            <description>Participants received a single oral dose of 40 mg apremilast.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) for Apremilast</title>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1790" spread="25.5"/>
                    <measurement group_id="O2" value="2360" spread="22.1"/>
                    <measurement group_id="O3" value="3500" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Terminal Elimination Half-life (T1/2) for Apremilast</title>
        <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Apremilast 20 mg</title>
            <description>Participants received a single oral dose of 20 mg apremilast.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Apremilast 30 mg</title>
            <description>Participants received a single oral dose of 30 mg apremilast.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Apremilast 40 mg</title>
            <description>Participants received a single oral dose of 40 mg apremilast.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Terminal Elimination Half-life (T1/2) for Apremilast</title>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="35.2"/>
                    <measurement group_id="O2" value="8.2" spread="44.4"/>
                    <measurement group_id="O3" value="7.4" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)</title>
        <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Apremilast 20 mg</title>
            <description>Participants received a single oral dose of 20 mg apremilast.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Apremilast 30 mg</title>
            <description>Participants received a single oral dose of 30 mg apremilast.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Apremilast 40 mg</title>
            <description>Participants received a single oral dose of 40 mg apremilast.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)</title>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>liters/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="25.5"/>
                    <measurement group_id="O2" value="12.7" spread="22.1"/>
                    <measurement group_id="O3" value="11.4" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)</title>
        <time_frame>Day 1 of each treatment period at predose (0 hour) and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Apremilast 20 mg</title>
            <description>Participants received a single oral dose of 20 mg apremilast.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Apremilast 30 mg</title>
            <description>Participants received a single oral dose of 30 mg apremilast.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Apremilast 40 mg</title>
            <description>Participants received a single oral dose of 40 mg apremilast.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)</title>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="47.6"/>
                    <measurement group_id="O2" value="151" spread="49.6"/>
                    <measurement group_id="O3" value="122" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Area Under the Plasma Concentration-time Curve During a Dosage Interval (AUCτ) for Apremilast</title>
        <description>Area under the plasma concentration-time curve during a dosage interval (tau) at steady state, where tau is 12 hours.</description>
        <time_frame>Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Apremilast 30 mg BID</title>
            <description>Participants received 30 mg apremilast orally twice a day (BID) for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Plasma Concentration-time Curve During a Dosage Interval (AUCτ) for Apremilast</title>
          <description>Area under the plasma concentration-time curve during a dosage interval (tau) at steady state, where tau is 12 hours.</description>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1610" spread="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2600" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Maximum Observed Plasma Concentration (Cmax) of Apremilast</title>
        <time_frame>Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Apremilast 30 mg BID</title>
            <description>Participants received 30 mg apremilast orally twice a day (BID) for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Maximum Observed Plasma Concentration (Cmax) of Apremilast</title>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</title>
        <time_frame>Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Apremilast 30 mg BID</title>
            <description>Participants received 30 mg apremilast orally twice a day (BID) for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast</title>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Terminal Elimination Half-life (T1/2) for Apremilast</title>
        <time_frame>Day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours after the morning dose</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Apremilast 30 mg BID</title>
            <description>Participants received 30 mg apremilast orally twice a day (BID) for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Terminal Elimination Half-life (T1/2) for Apremilast</title>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.80" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)</title>
        <time_frame>Day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours after the morning dose</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Apremilast 30 mg BID</title>
            <description>Participants received 30 mg apremilast orally twice a day (BID) for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Clearance of Apremilast From Plasma After Extravascular Administration (CL/F)</title>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>liters/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)</title>
        <time_frame>Day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours after the morning dose</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Apremilast 30 mg BID</title>
            <description>Participants received 30 mg apremilast orally twice a day (BID) for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Volume of Distribution of Apremilast During the Terminal Phase (Vz/F)</title>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Ratio of Accumulation</title>
        <description>Ratio of accumulation calculated as Day 14 AUC0-τ / Day 1 AUC0-τ</description>
        <time_frame>Day 1 and day 14 prior to the morning dose (0 hour), and at 0.5, 1, 1.5, 2, 3, 5, 8, and 12 hours after the morning dose, and on day 14 only at 24, 36, 48, 60, and 72 hours after the morning dose</time_frame>
        <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Apremilast 30 mg BID</title>
            <description>Participants received 30 mg apremilast orally twice a day (BID) for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Ratio of Accumulation</title>
          <description>Ratio of accumulation calculated as Day 14 AUC0-τ / Day 1 AUC0-τ</description>
          <population>Participants who received at least 1 dose of apremilast and had at least 1 measurable concentration datum.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (AEs)</title>
        <time_frame>Part 1, up to 40 days; Part 2, up to 24 days</time_frame>
        <population>Participants who received at least 1 dose of apremilast.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Apremilast 20 mg</title>
            <description>Participants received a single oral dose of 20 mg apremilast.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Apremilast 30 mg</title>
            <description>Participants received a single oral dose of 30 mg apremilast.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Apremilast 40 mg</title>
            <description>Participants received a single oral dose of 40 mg apremilast.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Apremilast 30 mg BID</title>
            <description>Participants received 30 mg apremilast orally twice a day for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Placebo BID</title>
            <description>Participants received matching placebo orally twice a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (AEs)</title>
          <population>Participants who received at least 1 dose of apremilast.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events related o study dug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAE leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part 1, up to 40 days; Part 2, up to 24 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Apremilast 20 mg</title>
          <description>Participants received a single oral dose of 20 mg apremilast.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Apremilast 30 mg</title>
          <description>Participants received a single oral dose of 30 mg apremilast.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: Apremilast 40 mg</title>
          <description>Participants received a single oral dose of 40 mg apremilast.</description>
        </group>
        <group group_id="E4">
          <title>Part 1: Total</title>
          <description>Participants received a single oral dose of 20 mg apremilast, 30 mg apremilast, and 40 mg apremilast across 3 treatment periods separated by a washout period of 7-10 days.</description>
        </group>
        <group group_id="E5">
          <title>Part 2: Apremilast 30 mg BID</title>
          <description>Participants received 30 mg apremilast orally twice a day for 14 days.</description>
        </group>
        <group group_id="E6">
          <title>Part 2: Placebo BID</title>
          <description>Participants received matching placebo orally twice a day for 14 days.</description>
        </group>
        <group group_id="E7">
          <title>Part 2: Total</title>
          <description>Participants who received 30 mg apremilast or placebo twice a day for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

